Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract 7, “A Randomized Comparison of Daunorubicin 90 mg/m2 vs 60 mg/m2 in AML Induction: Results From the UK NCRI AML17 Trial in 1206 Patients,” presented by Alan K. Burnett, MD.
Time: 1:29
Ayalew Tefferi, MD, of the Mayo Clinic, on abstract 403, “A Compendium of Cytogenetic Abnormali...
Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 229, “Caplacizumab, ...
Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract LBA-5, “...
2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 379,
Laurie Sehn, MD, of the BC Cancer Agency, on abstract 625, “Sustained Remission With the Combin...